| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Acetyl-L-lysine targets enzymes involved in lysine acetylation and deacetylation. It serves as a substrate for histone deacetylases (HDACs) and histone acetyltransferases (HATs). It is an important mechanism of epigenetics, regulating gene expression by modifying histone proteins.
|
|---|---|
| ln Vitro |
In vitro, Acetyl-L-lysine is used as a substrate to study HDAC activity. It can be incorporated into synthetic peptides to generate acetylated proteins for structural and functional studies. It is also used as a standard in proteomics to identify acetylation sites by mass spectrometry.
|
| ln Vivo |
In animal studies, Acetyl-L-lysine is administered to rodents to investigate protein acetylation in the context of metabolic diseases, such as diabetes and obesity. It can be used to supplement lysine in special diets and to study the role of lysine acetylation in gene regulation and cell signaling.
|
| Enzyme Assay |
Non-cell assays for HDAC activity using Acetyl-L-lysine involve a fluorogenic substrate (e.g., Boc-L-Lys(ε-acetyl)-MCA). HDAC cleaves the acetyl group, followed by trypsin cleavage to release the fluorescent MCA group. Fluorescence (excitation 355 nm, emission 460 nm) is measured over time. Acetyl-L-lysine itself can be used as a competitive inhibitor in such assays.
|
| Cell Assay |
HeLa or HEK293 cells are treated with Acetyl-L-lysine (1-10 mM) to increase intracellular levels of acetylated lysine. Acetylation of histones and other nuclear proteins is analyzed by Western blot using an anti-acetyl-lysine antibody. Alternatively, cells are lysed and acetylated peptides are immunoprecipitated using acetyl-lysine antibody for proteomic analysis by LC-MS/MS.
|
| Animal Protocol |
In animal studies, Acetyl-L-lysine is typically administered to rodents by oral gavage (50-200 mg/kg) or intraperitoneal injection. It is also added to drinking water for chronic studies. Blood and tissue samples (liver, muscle) are collected to analyze lysine acetylation levels by Western blot or MS. It can also be used in metabolic cage studies to collect urine for analysis.
|
| ADME/Pharmacokinetics |
Acetyl-L-lysine is stable in circulation and can be deacetylated by HDACs to release free lysine, which is then available for protein synthesis or further metabolism. It has good oral bioavailability (estimated 30-60%) and is distributed to all tissues, including the brain. Its plasma half-life is approximately 3-5 hours. It is renally cleared.
|
| Toxicity/Toxicokinetics |
Acetyl-L-lysine is non-toxic at the doses used in research (50-200 mg/kg). High doses may cause mild gastrointestinal distress. The compound is generally recognized as safe for use as a nutritional supplement and laboratory research tool. No organ toxicity has been reported.
|
| Additional Infomation |
N(2)-acetyl-L-lysine is an L-lysine derivative with the acetyl group at the N(2) position. It is a human metabolite and a zwitterion tautomer of N(2)-acetyl-L-lysine. N-α-acetyl-L-lysine has been reported in Arabidopsis thaliana, fission yeast, and other organisms with relevant data.
Acetyl-L-lysine is used as a research tool to study protein acetylation and deacetylation, as an internal standard for the quantification of acetylated amino acids by mass spectrometry, and as a building block in peptide synthesis. It is also used to study the role of lysine acetylation in cancer, neurodegeneration, and metabolic disorders. It is not an approved drug. |
| Molecular Formula |
C8H16N2O3
|
|---|---|
| Molecular Weight |
188.22
|
| Exact Mass |
188.116
|
| CAS # |
1946-82-3
|
| PubChem CID |
92907
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
438.5±40.0 °C at 760 mmHg
|
| Melting Point |
256 - 258 °C
|
| Flash Point |
219.0±27.3 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.490
|
| LogP |
-1.42
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
13
|
| Complexity |
182
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)N[C@@H](CCCCN)C(=O)O
|
| InChi Key |
VEYYWZRYIYDQJM-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C8H16N2O3/c1-6(11)10-7(8(12)13)4-2-3-5-9/h7H,2-5,9H2,1H3,(H,10,11)(H,12,13)/t7-/m0/s1
|
| Chemical Name |
(2S)-2-acetamido-6-aminohexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :≥ 100 mg/mL (~531.29 mM)
DMSO :~25 mg/mL (~132.82 mM (<60 ℃)；酸性条件溶解 (HCL 调节，pH=3) ) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3129 mL | 26.5647 mL | 53.1293 mL | |
| 5 mM | 1.0626 mL | 5.3129 mL | 10.6259 mL | |
| 10 mM | 0.5313 mL | 2.6565 mL | 5.3129 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
